Connective tissue disorder
Therapeutic area
Rheumatology
Rare disease
No
- Definition
- A disease involving the connective tissue.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Connective tissue disorder
- Therapeutic area
- Rheumatology
- connective tissue disorder
- connective tissue disease
- connective tissue disease or disorder
- connective tissue diseases
- connective tissue disorder
- connective tissue disorders
- disease of connective tissue
- disease or disorder of connective tissue
- disease, connective tissue
- disorder of connective tissue
- primary disorder of connective tissue
- tissue disease, connective
- All therapeutic areas
- Rheumatology
- Severity
- Unknown
- MONDO ID
- MONDO:0003900
- Parent condition
- MONDO:7770006
Related records
Broader conditions (3)
- Disease
- Disease by body system or component
- Human disease
Narrower conditions (905)
- Achilles bursitis
- Achondrogenesis type II
- Acquired polycythemia vera
- Acroosteolysis dominant type
- ACTH-producing pituitary gland adenoma
- ACTH-producing pituitary gland carcinoma
- ACTH-producing pituitary gland neoplasm
- Acute basophilic leukemia
- Acute biphenotypic leukemia
- Acute erythroid leukemia
- Acute leukemia of ambiguous lineage
- Acute megakaryoblastic leukemia
- Acute megakaryoblastic leukemia in adult
- Acute megakaryoblastic leukemia in down syndrome
- Acute megakaryoblastic leukemia without down syndrome
- Acute monocytic leukemia
- Acute myeloblastic leukemia with maturation
- Acute myeloblastic leukemia without maturation
- Acute myeloid leukemia
- Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Trials (194)
- 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
- A Clinical Trial for CTD-ILD Treatment
- A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
- A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
- A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
- A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis
- A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
- A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
- A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
- A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
- A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
- A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
- A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
- A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Approved drugs (1)
- Sildenafil citrate
Drugs in development (1)
- Belimumab Phase 3